Odefsey vs Genvoya

Genvoya and Odefsey are both first-line treatment regimens for Human Immunodeficiency Virus type 1 released by the pharmaceutical company Gilead Sciences Inc. They also both contain emtricitabine and the novel tenofovir prodrug called tenofovir alafenamide (TAF). Their main difference, in terms of drug composition, is the addition of the booster cobicistat in Genvoya. Odefsey was given FDA approval a year after Genvoya hit the market. For years, combination antiretroviral therapy (ART) has been the mainstay of treatment for HIV-1 infection. These regimens resulted to rapid reduction of viral RNA, improved immune function, and reduced mortality.

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Genvoya is a fixed dose, 4-in-1 combination treatment regimen for HIV infection that can be given to patients with impaired kidney function. It contains two NRTIs (nucleoside/nucleotide reverse transcriptase inhibitor) emtricitabine and tenofovir and one INSTI (integrase strand transfer inhibitor) elvitegravir. Cobicistat is added to enhance the effects of these anti-HIV drugs. The old tenofovir (TDF) was replaced with a new prodrug TAF, which is found to be less toxic to kidneys and bones. While there are fewer side effects associated with Genvoya, TAF may cause an increase in cholesterol and triglyceride levels in the blood. The pharmacokinetic booster cobicistat may also interact with many drugs and cause additional adverse effects.

Find out the cost of Genvoya at Kangaroo.co!

Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide)

Odefsey is a complete, single-tablet, anti-HIV prescription medication used to treat adult patients and adolescents 12 years of age and older. It is a TAF-based antiretroviral regimen, which is an upgraded version of Complera. Despite the many disadvantages of Complera, you can stay with your current regimen if you are not experiencing bothersome side effects that hinder treatment adherence. If you have not received ART before, and you want to protect yourself from possible kidney impairment and bone density loss, Odefsey is worth considering.

Find out the cost of Odefsey at Kangaroo.co!

Genvoya vs Odefsey comparison chart

NRTI serves as the backbone of ART. Tenofovir, in the form of tenofovir disoproxil fumarate (TDF), is one of the most widely used NRTIs in previously recommended antiretroviral regimens. However, long-term exposure to TDF is also associated with kidney impairment and bone density loss. Now that HIV/AIDS patients are living longer from antiretroviral treatments, the release of Genvoya and Odefsey is a necessary step in addressing the long-term health effects of ART in a patient population with an improving life expectancy. Talk to your health care provider if you want to know if Genvoya or Odefsey is the best regimen for you.